Anti-inflammatory effects and gastrointestinal safety of NNU-hdpa, a novel dual COX/5-LOX inhibitor

European Journal of Pharmacology

Volumn 611, Issue 1-3, 2009, Pages 100-106

  Xu, Guang Lin ^a   Liu, Fei ^a   Ao, Gui Zhen ^c   He, Shu Ying ^b   Ju, Min ^a   Zhao, Yue ^a   Xue, Ting ^a  

^a NANJING NORMAL UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

Anti inflammatory; COX 5 LOX; Edema; LTB4; PGE2

Indexed keywords

2 (4 HYDROXYLPHENYL) 3 (3,5 DIHYDROXYLPHENYL)PROPENOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; CARRAGEENAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE B4; LIPOPOLYSACCHARIDE; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; RESVERATROL; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; XYLENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG STRUCTURE; EAR EDEMA; EDEMA; ENZYME INHIBITION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; STATISTICAL ANALYSIS; STOMACH LESION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONATE 5-LIPOXYGENASE; CARRAGEENAN; CELL LINE; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DRUG TOXICITY; EDEMA; INTRACELLULAR SPACE; LEUKOTRIENE B4; MACROPHAGES; MALE; MICE; NF-KAPPA B; PHENYLPROPIONATES; PROPIONIC ACIDS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; SIGNAL TRANSDUCTION; STOMACH ULCER; XYLENES;

EID: 67349217821     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.03.062     Document Type: Article

References (36)

1. Bardelli C., Gunella G., Varsaldi F., Balbo P., Del Boca E., Bernardone I.S., Amoruso A., and Brunelleschi S. Expression of functional NK1 receptors in human alveolar macrophages: superoxide anion production, cytokine release and involvement of NF-κB pathway. Br. J. Pharmacol. 145 (2005) 385-396
2. Bertolini A., Ottani A., and Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr. Med. Chem. 9 (2002) 1033-1043
3. Brune K. Safety of anti-inflammatory treatment - new ways of thinking. Rheumatology 43 Suppl. 1 (2004) i16-i20
4. Coruzzi G., Venturi N., and Spaggiari S. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond. Acta Biomed. 78 (2007) 96-110
5. Das S., and Das D.K. Anti-inflammatory responses of resveratrol. Inflamm. Allergy Drug Targets 6 (2007) 168-173
6. Del Soldato P., Sorrentino R., and Pinto A. NO-aspirins: a class of new antiinflammatory and antithrombotic agents. Trends Pharmacol. Sci. 20 (1999) 319-323
7. De Winther M.P., Kanters E., Kraal G., and Hofker M.H. Nuclear factor κB signaling in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 904-914
8. Fiorucci S., Meli R., Bucci M., and Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?. Biochem. Pharmacol. 62 (2001) 1433-1438
9. Gyömber E., Vattay P., Szabo S., and Rainsford K.D. Effect of lipoxygenase inhibitors and leukotriene antagonists on acute and chronic gastric haemorrhagic mucosal lesions in ulcer models in the rat. J. Gastroenterol. Hepatol. 11 (1996) 922-927
10. Hoogstraate J., Andersson L.I., Berge O.G., Jonzon B., and Ojteg G. COX-inhibiting nitric oxide donators (CINODs) - a new paradigm in the treatment of pain and inflammation. Inflammopharmacology 11 (2003) 423-428
11. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., and Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275 (1997) 218-220
12. Juan M.E., Vinardell M.P., and Planas J.M. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J. Nutr. 132 (2002) 257-260
13. Kim Y.A., Lim S.Y., Rhee S.H., Park K.Y., Kim C.H., Choi B.T., Lee S.J., Park Y.M., and Choi Y.H. Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in beta-amyloid-treated C6 glioma cells. Int. J. Mol. Med. 17 (2006) 1069-1075
14. Kitagawa H., Takeda F., and Kohei H. Effect of endothelium-derived relaxing factor on the gastric lesion induced by HCl in rats. J. Pharmacol. Exp. Ther. 253 (1990) 1133-1137
15. Kneen, G., Jackson, W.P., Islip, P.J., Wates, P.J. Preparation of arylhydroxamic acid derivative compositions containing them, and their use in medicine and other applications. European Patent 196 184. 1986-10-01.
16. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 120 (2001) 594-606
17. Lappas M., Permezel M., Georgiou H.M., and Rice G.E. Nuclear factor kappa B regulation of proinflammatory cytokines in human gestational tissues in vitro. Biol. Reprod. 67 (2002) 668-673
18. Li Q., and Verma I.M. NF-κB regulation in the immune system. Nat. Rev., Immunol. 2 (2002) 725-734
19. Martel-Pelletier J., Lajeunesse D., Reboul P., and Pelletier J.P. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal antiinflammatory drugs. Ann. Rheum. Dis. 62 (2003) 501-509
20. Martín A.R., Villegas I., Sánchez-Hidalgo M., and de la Lastra C.A. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br. J. Pharmacol. 147 (2006) 873-885
21. Martinez J., and Moreno J.J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol. 59 (2000) 865-870
22. Olajide O.A., Makinde J.M., Okpako D.T., and Awe S.O. Studies on the anti-inflammatory and related pharmacological properties of the aqueous extract of Bridelia ferruginea stem bark. J. Ethnopharmacol. 71 (2000) 153-160
23. Ong C.K., Lirk P., Tan C.H., and Seymour R.A. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin. Med. Res. 5 (2007) 19-34
24. Parente L. Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one?. J. Rheumatol. 28 (2001) 2375-2382
25. Rao P.N., Chen Q.H., and Knaus E.E. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases. J. Med. Chem. 49 (2006) 1668-1683
26. Shankar S., Singh G., and Srivastava R.K. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front. Biosci. 12 (2007) 4839-4854
27. Surh Y.J., Chun K.S., Cha H.H., Han S.S., Keum Y.S., and Park K.K. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF kappa B activation. Mutat. Res. 480 (2001) 243-268
28. Tam S.W., Saha J.K., Garvey D.S., Schroeder J.D., Shelekhin T.E., and Janero D.R. Nitrosothiol-based NO-donors inhibit the gastrointestinal mucosal damaging actions of NSAIDs. Inflammopharmacology 8 (2000) 81-88
29. Uddin M.J., Praveen Rao P.N., McDonald R., and Knaus E.E. A new class of acyclic 2-alkyl-1,1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 47 (2004) 6108-6111
30. Wallace J.L., and Cirino G. The development of gastrointestinalsparing nonsteroidal antiinflammatory drugs. Trends Pharmacol. Sci. 15 (1994) 405-406
31. Wallace J.L., and Del Soldato P. The therapeutic potential of NO-NSAIDs. Fund Clin. Pharmacol. 17 (2003) 11-20
32. Wallace J.L., McKnight G.W., Keenan C.M., Byles N.I., and MacNaughton W.K. Effects of leukotrienes on susceptibility of the rat stomach to damage and investigation of the mechanism of action. Gastroenterology 98 (1990) 1178-1186
33. Wallace J.L., Caliendo G., Santagada V., Cirino G., and Fiorucci S. Gastrointestinal safety and antiinflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 132 (2007) 261-271
34. Winter C.A., Risley E.A., and Nuss G.W. Carrageenan-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc. Soc. Exp. Biol. Med. 111 (1962) 544-552
35. Yang L.C., Marsala M., and Yaksh T.L. Characterization of time course of spinal amino acids, citrulline and PGE2 release after carrageenan/kaolin-induced knee joint inflammation: a chronic microdialysis study. Pain 67 (1996) 345-354
36. Yoshiyuki K., Hiromichi O., and Michinori K. Effects of stilbenes isolated from medicinal plants on arachidonate metabolism and degranulation in human polymorphonuclear leukocytes. J. Ethnopharmacol. 45 (1995) 131-139